However, in a genome-scale analysis by The Cancer Genome Atlas (TCGA) 26% (51/195) of all patients had genomic or transcriptome alterations, mostly mRNA up-regulation, in at least one of the FGFR genes or its adaptor proteins FRS2/3, thus implying that cancer cells might benefit from an increased FGF signaling5,38. This evidence concerns the gene FRS2 and cancer.